{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["3(3)"],"submitter":["Arnold SV"],"pubmed_abstract":["<h4>Background</h4>A number of non-low-density lipoprotein cholesterol lipid abnormalities are associated with type 2 diabetes and insulin resistance, which may lead practitioners to use medications targeting these abnormal lipid fractions despite a lack of evidence or guideline recommendations.<h4>Methods and results</h4>Among 382 921 US patients with type 2 diabetes (69% with cardiovascular disease, 76% on a statin), 95 995 (26%) were on some nonstatin lipid-lowering medication-19 265 (5%) on niacin, 32 919 (9%) on a fibrate and 69 513 (18%) on fish oil. Use of all three medications was stable over time and higher in patients with cardiovascular disease and with higher triglyceride levels, although even among patients with triglyceride levels <2.3 mmol/L, 6% were on a fibrate and 17% wer"],"journal":["Endocrinology, diabetes & metabolism"],"pagination":["e00126"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7375067"],"repository":["biostudies-literature"],"pubmed_title":["Use of non-LDL-C lipid-lowering medications in patients with type 2 diabetes."],"pmcid":["PMC7375067"],"pubmed_authors":["Wong ND","Arnold SV","Kosiborod M","Goyal A","Gosch K","Hejjaji V","Leiter LA"],"additional_accession":[]},"is_claimable":false,"name":"Use of non-LDL-C lipid-lowering medications in patients with type 2 diabetes.","description":"<h4>Background</h4>A number of non-low-density lipoprotein cholesterol lipid abnormalities are associated with type 2 diabetes and insulin resistance, which may lead practitioners to use medications targeting these abnormal lipid fractions despite a lack of evidence or guideline recommendations.<h4>Methods and results</h4>Among 382 921 US patients with type 2 diabetes (69% with cardiovascular disease, 76% on a statin), 95 995 (26%) were on some nonstatin lipid-lowering medication-19 265 (5%) on niacin, 32 919 (9%) on a fibrate and 69 513 (18%) on fish oil. Use of all three medications was stable over time and higher in patients with cardiovascular disease and with higher triglyceride levels, although even among patients with triglyceride levels <2.3 mmol/L, 6% were on a fibrate and 17% wer","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2026-07-15T23:38:25.551Z","creation":"2025-04-19T11:39:56.453Z"},"accession":"S-EPMC7375067","cross_references":{"pubmed":["32704552"],"doi":["10.1002/edm2.126"]}}